Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND IBUPROFEN vs FIRMAGON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively binds to Gn RH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone production in males.
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
FDA-approved for advanced prostate cancer (hormone-sensitive, metastatic or locally advanced),Off-label: Treatment of uterine fibroids, endometriosis, and precocious puberty
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
For advanced prostate cancer: 120 mg subcutaneously as a loading dose (two 60 mg injections), then 80 mg subcutaneously once monthly (one 80 mg injection) starting 28 days after the loading dose.
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Terminal elimination half-life is approximately 63 days after subcutaneous administration in patients with prostate cancer, allowing for monthly dosing schedules.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Degraded into peptides and amino acids; not a substrate for CYP450 enzymes.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Primarily hepatobiliary; about 90% of the dose is eliminated in feces as unchanged drug, with less than 5% excreted renally as unchanged drug and metabolites.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
Volume of distribution is approximately 10 L, indicating limited extravascular distribution consistent with a large peptide.
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
Subcutaneous administration: Bioavailability is approximately 50% relative to intravenous administration, with absorption characterized by a slow and sustained release profile.
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min). Use with caution.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
Safety and efficacy in pediatric patients have not been established. Not indicated for use in children.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
No specific dose adjustment is recommended for elderly patients. Monitor for cardiovascular events and changes in bone density due to androgen deprivation.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Increased risk of QT interval prolongation; use caution in patients with congenital long QT syndrome, electrolyte abnormalities, or concomitant use of QT-prolonging drugs. Also, hypersensitivity reactions including anaphylaxis have been reported.
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
QT prolongation and ventricular arrhythmias (especially with hypokalemia or bradycardia),Hypersensitivity reactions (urticaria, angioedema, anaphylaxis),Tumor flare reaction (transient worsening of symptoms due to initial testosterone surge) - less common with degarelix compared to Gn RH agonists,Loss of bone mineral density with long-term use,Injection site reactions (pain, erythema, nodule, necrosis),Increased hepatic enzymes (transient and usually asymptomatic),Hyperglycemia and increased risk of diabetes (monitor blood glucose),Cardiovascular risks (myocardial infarction, stroke) in patients with pre-existing conditions
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Hypersensitivity to degarelix or any component of the formulation,Women of reproductive potential (pregnancy category X; can cause fetal harm),Severe renal impairment (Cr Cl < 30 m L/min) - insufficient data,Severe hepatic impairment (Child-Pugh class C) - not studied
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
No significant food interactions. Avoid grapefruit juice if also taking certain antiarrhythmics or other QT-prolonging drugs. Maintain adequate calcium and vitamin D intake if at risk for bone loss.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
FIRMAGON (degarelix) is contraindicated in pregnancy. Gn RH antagonists like degarelix can cause fetal harm when administered to a pregnant woman. Based on findings from animal studies and its mechanism of action, degarelix is expected to increase the risk of first trimester pregnancy loss. Adequate human data are not available, but the drug should be avoided during pregnancy. If exposure occurs, inform the patient of the potential hazard.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
It is not known whether degarelix is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from degarelix, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
No dosage adjustment studies have been conducted in pregnant women. Degarelix is contraindicated in pregnancy, and use should be avoided. If inadvertent exposure occurs, no specific dose adjustment is recommended; instead, the drug should be discontinued and the patient counseled about fetal risks.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
FIRMAGON (degarelix) is a Gn RH antagonist indicated for advanced prostate cancer. It does not cause testosterone flare like Gn RH agonists. Monitor serum calcium in patients with bone metastases due to risk of hypercalcemia. Injection site reactions are common; rotate sites and apply warm compresses. Use with caution in patients with congenital long QT syndrome or those on Class IA/III antiarrhythmics.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
This medication is given as an injection under the skin, usually every month.,It may cause injection site reactions like redness, swelling, or pain; applying a warm compress can help.,You may experience hot flashes, decreased libido, or erectile dysfunction.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or unusual bleeding/bruising.,Regular blood tests are needed to monitor response and side effects.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND IBUPROFEN vs FIRMAGON, answered by our medical review team.
ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. FIRMAGON is a GnRH Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively binds to Gn RH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone production in males.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND IBUPROFEN and FIRMAGON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. The standard adult dose of FIRMAGON is: For advanced prostate cancer: 120 mg subcutaneously as a loading dose (two 60 mg injections), then 80 mg subcutaneously once monthly (one 80 mg injection) starting 28 days after the loading dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND IBUPROFEN and FIRMAGON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. FIRMAGON is classified as Category C. FIRMAGON (degarelix) is contraindicated in pregnancy. GnRH antagonists like degarelix can cause fetal harm when administered to a pregnant woman. Based on findings from animal stud. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.